Source: Health Canada shortage reports · Updated Aug 13, 2026
Cabergoline is in a widespread shortage in Canada. 2 of 3 reported products are affected. The latest manufacturer estimate for full recovery is Oct 2, 2026.
A dopamine agonist used to treat conditions caused by high prolactin levels.
Products affected
2 / 3
In shortage since
Jan 1, 2015
Est. full return
Oct 2, 2026
Reports on file
13
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
APO-CABERGOLINE
0.5MG · TABLET · APOTEX INC
DIN 02455897 · since Aug 11, 2026, est. end Oct 2, 2026 · Disruption of the manufacture of the drug.
Active shortage
ACT CABERGOLINE
0.5MG · TABLET · ACTAVIS PHARMA COMPANY
DIN 02301407 · since Jan 1, 2015, no end estimate · Requirements related to complying with good manufacturing practices.
Resolved
APO-CABERGOLINE
0.5MG · TABLET · APOTEX INC
DIN 02455897 · ended Jul 3, 2025 · Disruption of the manufacture of the drug.
Resolved
DOSTINEX
0.5MG · TABLET · PFIZER CANADA ULC
DIN 02242471 · ended Oct 17, 2024 · Demand increase for the drug.
Resolved
APO-CABERGOLINE
0.5MG · TABLET · APOTEX INC
DIN 02455897 · ended Oct 7, 2024 · Disruption of the manufacture of the drug.
Resolved
APO-CABERGOLINE
0.5MG · TABLET · APOTEX INC
DIN 02455897 · ended Dec 15, 2023 · Disruption of the manufacture of the drug.
Resolved
APO-CABERGOLINE
0.5MG · TABLET · APOTEX INC
DIN 02455897 · ended Mar 1, 2021 · Disruption of the manufacture of the drug.
Resolved
DOSTINEX
0.5MG · TABLET · PFIZER CANADA ULC
DIN 02242471 · ended Dec 20, 2019 · Demand increase for the drug.
Resolved
DOSTINEX
0.5MG · TABLET · PFIZER CANADA ULC
DIN 02242471 · ended Sep 9, 2019 · Demand increase for the drug.
Resolved
DOSTINEX
0.5MG · TABLET · PFIZER CANADA INC
DIN 02242471 · ended Dec 20, 2018 · Demand increase for the drug.
Resolved
DOSTINEX
0.5MG · TABLET · PFIZER CANADA INC
DIN 02242471 · ended Nov 21, 2018 · Demand increase for the drug.
Resolved
DOSTINEX
0.5MG · TABLET · PFIZER CANADA INC
DIN 02242471 · ended Mar 7, 2018 · Demand increase for the drug.
Showing 12 of 13 reports. All reports are on file with Health Canada.
What's happening
Cabergoline is currently affected by 2 active shortage reports filed with Health Canada by APOTEX INC, ACTAVIS PHARMA COMPANY.
The reported causes are: disruption of the manufacture of the drug; requirements related to complying with good manufacturing practices. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Cabergoline is classified under “OTHER GYNECOLOGICALS” (ATC G02CB).
Recent changes
Aug 13, 2026
New report filed
Common questions
What is Cabergoline used for?
A dopamine agonist used to treat conditions caused by high prolactin levels.
When will Cabergoline be back in stock in Canada?
The latest manufacturer estimate is Oct 2, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Cabergoline in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.